Gamma Knife Advantages
Gamma Knife Perfexion treatment benefits:
- A single (one day), non-invasive treatment designed solely for treating intracranial diseases
- Typically an outpatient procedure with fewer complications than traditional surgery
- Bloodless and virtually painless with no loss of hair
- Does not require the use of general anesthesia
- Rapid return to pretreatment activities within days, requiring little or no rehabilitative services
- Reimbursed by most insurance companies, including Medicare
- Been in use for over 40 years with over 600,000 patients treated worldwide
- No other technology has the ability to treat multiple targets in the brain with the same clinical outcomes and speed
- Can treat single and multiple brain metastases from a variety of primary cancers such as breast, lung, colon, kidney, bladder, prostate and melanoma
- Can be used in conjunction with conventional surgery, other forms of radiation therapy and chemotherapy
- Can be performed without disruption of chemotherapy
- Provides unlimited reach to areas of the brain, and with future fixation devices, reach into the cervical spine
Over 600,000 patients in over 266 select facilities worldwide have been treated with the Gamma Knife. Following are treatment results for a few specific conditions:
- Metastatic tumors: Gamma Knife radiosurgery achieves control rates of 80-85%, essentially comparable to open surgery – without the risk of infection, bleeding or complications- and without a lengthy hospital stay and convalescence.
- Benign tumors: Follow-up of ten years demonstrates control rates in more than 90% of cases. 53% of tumors decrease in size while, 40% remain stable in size. In some cases, combined treatment with surgery and Gamma Knife offers the best opportunity for tumor control.
- Acoustic neuromas (vestibular schwannomas): Up to 98% of tumors either decrease in size or remain stable, with near complete facial nerve preservation, at six-year follow-up.
- Pituitary adenomas: Effective control in a majority of patients; particularly beneficial for residual or recurrent tumors following surgery.
- Vascular malformations such as arteriovenous malformations (AVMs): Complete obliteration of AVMs takes place in 60 to 70% of patients within two to three years of treatment.
- Trigeminal neuralgia: Initial pain relief in more than 80% of patients; long-term pain relief without medications in 63% of patients at four-year follow-up.